Video

Dr. Hurvitz on Using ADCs in HER2+ Breast Cancer

Sara A. Hurvitz, MD, associate professor of medicine and medical oncologist, University of California Los Angeles, discusses the use of antibody-drug conjugates in HER2-positive breast cancer.

Sara A. Hurvitz, MD, associate professor of medicine and medical oncologist, University of California Los Angeles, discusses the use of antibody-drug conjugates (ADCs) in HER2-positive breast cancer.

ADCs combine a very specifically targeted antibody that targets the tumor cells more than the normal cells with a cytotoxic payload, which is a very potent type of chemotherapy, explains Hurvitz. This allows the chemotherapy to be directed to the antigen-overexpressing tumor cell. By targeting chemotherapy directly to the antigen overexpressing tumor cells, the toxicity is limited in normal cells.

While patients get a very toxic type of chemotherapy with the ADCs, the chemotherapy targets the HER2 antigen; therefore, patients do not have hair loss and avoid other typical adverse events caused by cytotoxic chemotherapy.

<<< View more from 2019 San Antonio Breast Cancer Symposium

Related Videos
Ruth M. O’Regan, MD
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Sheldon M. Feldman, MD
Dana Zakalik, MD